We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
Read MoreHide Full Article
Key Takeaways
More than 175 emerging biotech companies have adopted Veeva Basics to streamline drug development operations.
VEEV's pre-configured applications help smaller biotechs simplify clinical, regulatory and quality processes.
Veeva Basics could drive recurring revenue growth as biotech customers expand operations & technology needs.
Veeva Systems (VEEV - Free Report) recently announced that more than 175 emerging biotechnology companies are using Veeva Basics to establish their technology infrastructure and streamline drug development operations. The growing adoption highlights the company’s efforts to expand its presence among early-stage biotechs.
From an investor’s perspective, increasing adoption among emerging biotechs could support Veeva Systems’ long-term growth by building customer relationships early and creating opportunities to expand as these companies advance toward commercialization. However, the financial impact will depend on continued customer adoption and the ability to convert this momentum into meaningful revenue growth.
Likely Trend of VEEV Stock Following the News
Following the announcement on Sept. 30, shares of VEEV traded flat on Oct. 7. Year to date, shares of the company have gained 32.5% compared with the industry’s 19.1% growth. However, the S&P 500 has risen 13.8% in the same timeframe.
The growing adoption of Veeva Basics could strengthen Veeva Systems’ long-term growth prospects by helping it establish relationships with emerging biotechs early in their development cycles. As these companies advance clinical programs and move toward commercialization, they may require additional applications across regulatory, quality, clinical and commercial functions, creating opportunities for Veeva Systems to expand its customer relationships and recurring revenues.
The platform’s pre-configured applications may also lower adoption barriers for smaller biotechs, broadening Veeva Systems’ addressable market and reinforcing its position in the life sciences software industry. However, the long-term benefits will depend on customer retention, expansion opportunities and the pace at which these biotechs scale their operations.
VEEV currently has a market capitalization of $47.95 billion.
Image Source: Zacks Investment Research
Veeva Basics Streamlines Operations for Emerging Biotechs
Veeva Basics is designed to help emerging biotechnology companies establish a technology infrastructure without the complexity and costs associated with building customized systems. Built on VEEV’s Vault Platform, the offering provides pre-configured and pre-validated applications across clinical, regulatory, quality, medical and commercial functions. According to the company, customers can implement these applications in weeks and expand their capabilities as the businesses grow.
This approach is particularly relevant for smaller biotechs with limited IT resources that need to maintain compliance while advancing drug development programs. Whitehawk Therapeutics, for instance, highlighted improvements in regulatory and quality processes after replacing paper-based workflows with Veeva Systems solutions, while Structure Therapeutics reported better quality control and faster regulatory timelines after bringing submission publishing in-house.
Regulatory Publishing Moves In-House
A key development is the growing use of Veeva Submissions Publishing Basics, which enables biotech companies to prepare regulatory submissions and manage interactions with health authorities internally rather than relying entirely on external service providers. For companies preparing their first submissions to the FDA, the application is designed to improve visibility and control throughout the regulatory process.
Structure Therapeutics cited better quality control and faster regulatory timelines following the adoption of the solution. By helping smaller biotechs manage complex regulatory requirements more efficiently, VEEV is addressing an important operational challenge in drug development. The broader adoption of Veeva Basics could also create opportunities to deepen customer relationships as these companies expand their technology needs, although the announcement did not quantify the expected revenue contribution from the offering.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
VEEV continues to strengthen its position in the life sciences software market as the Veeva DQS platform expands reach across clinical trials. The company said that the solution has now supported data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.
The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
Key Takeaways
Veeva Systems (VEEV - Free Report) recently announced that more than 175 emerging biotechnology companies are using Veeva Basics to establish their technology infrastructure and streamline drug development operations. The growing adoption highlights the company’s efforts to expand its presence among early-stage biotechs.
From an investor’s perspective, increasing adoption among emerging biotechs could support Veeva Systems’ long-term growth by building customer relationships early and creating opportunities to expand as these companies advance toward commercialization. However, the financial impact will depend on continued customer adoption and the ability to convert this momentum into meaningful revenue growth.
Likely Trend of VEEV Stock Following the News
Following the announcement on Sept. 30, shares of VEEV traded flat on Oct. 7. Year to date, shares of the company have gained 32.5% compared with the industry’s 19.1% growth. However, the S&P 500 has risen 13.8% in the same timeframe.
The growing adoption of Veeva Basics could strengthen Veeva Systems’ long-term growth prospects by helping it establish relationships with emerging biotechs early in their development cycles. As these companies advance clinical programs and move toward commercialization, they may require additional applications across regulatory, quality, clinical and commercial functions, creating opportunities for Veeva Systems to expand its customer relationships and recurring revenues.
The platform’s pre-configured applications may also lower adoption barriers for smaller biotechs, broadening Veeva Systems’ addressable market and reinforcing its position in the life sciences software industry. However, the long-term benefits will depend on customer retention, expansion opportunities and the pace at which these biotechs scale their operations.
VEEV currently has a market capitalization of $47.95 billion.
Image Source: Zacks Investment Research
Veeva Basics Streamlines Operations for Emerging Biotechs
Veeva Basics is designed to help emerging biotechnology companies establish a technology infrastructure without the complexity and costs associated with building customized systems. Built on VEEV’s Vault Platform, the offering provides pre-configured and pre-validated applications across clinical, regulatory, quality, medical and commercial functions. According to the company, customers can implement these applications in weeks and expand their capabilities as the businesses grow.
This approach is particularly relevant for smaller biotechs with limited IT resources that need to maintain compliance while advancing drug development programs. Whitehawk Therapeutics, for instance, highlighted improvements in regulatory and quality processes after replacing paper-based workflows with Veeva Systems solutions, while Structure Therapeutics reported better quality control and faster regulatory timelines after bringing submission publishing in-house.
Regulatory Publishing Moves In-House
A key development is the growing use of Veeva Submissions Publishing Basics, which enables biotech companies to prepare regulatory submissions and manage interactions with health authorities internally rather than relying entirely on external service providers. For companies preparing their first submissions to the FDA, the application is designed to improve visibility and control throughout the regulatory process.
Structure Therapeutics cited better quality control and faster regulatory timelines following the adoption of the solution. By helping smaller biotechs manage complex regulatory requirements more efficiently, VEEV is addressing an important operational challenge in drug development. The broader adoption of Veeva Basics could also create opportunities to deepen customer relationships as these companies expand their technology needs, although the announcement did not quantify the expected revenue contribution from the offering.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
VEEV continues to strengthen its position in the life sciences software market as the Veeva DQS platform expands reach across clinical trials. The company said that the solution has now supported data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.
The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity.
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.